The labeled Trz-conjugated Pal-pHSNs (Trz-Pal-pHSNs) exhibited significant cytotoxic effects, indicating their potential as personalized medicine for the treatment of HER2-positive breast cancer (Figure 7) [116]. Here, ERBB2 is linked to breast carcinoma.